Barbara Weber - 01 Feb 2022 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Executive Officer, Director
Signature
/s/ Douglas Barry, as attorney-in-fact
Issuer symbol
TNGX
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
03 Feb 2022, 15:30:33 UTC
Previous filing
27 Oct 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +625,000 $0.000000 625,000 01 Feb 2022 Common Stock 625,000 $9.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter.